Drug Discovery Outsourcing Market Size To Reach US$ 6.55 Bn By 2030 Size To Reach US$ 6.55 Bn By 2030

The global drug discovery outsourcing market size was estimated at US$ 3.62 billion in 2021 and is expected to hit over US$ 6.55 billion by 2030, poised to grow at a CAGR of 6.8% from 2021 to 2030.

The technological advancements in the pharmaceutical industry, increasing investments in the research & development, rising prevalence of various chronic diseases, and rising popularity of the biologics are some of the most important drivers of the global drug discovery outsourcing market. The surging demand for the biologics across the globe is expected to be a significant driver of the market. The growing geriatric population and growing prevalence of non-communicable diseases such as cancer, chronic obstructive pulmonary diseases, cardiovascular diseases, and diabetes is encouraging the pharmaceutical companies to outsource the drug discovery activities to the third-person service providers.

Get the Sample Pages of Report@ https://www.precedenceresearch.com/sample/1549

As per the United Nations, the geriatric population across the globe is estimated to reach 2 billion by 2050. The presence of numerous contract research organizations and contract manufacturing organizations are facilitating the drug discovery activities and contributing significantly towards the market growth.

Report Highlights

Based on the workflow, the lead identification & candidate optimization segment accounted for a market share of around 32% and dominated the global drug discovery outsourcing market in 2020. This is attributed to the economy of scale and higher efficiencies associated with this workflow. Furthermore, the increasing adoption of computer aided drug discovery and silico techniques is supplementing the market growth.
Based on the therapeutic area, the respiratory is estimated to be the most opportunistic segment. The growing number of respiratory patients is attracting investments towards the drug discovery for the treatment of respiratory diseases. According to the World Health Organization, around 65 million people across the globe suffers from COPD and around 3 million dies due to it every year.
Based on the drug type, the small molecules segment dominated the market in 2020. The small molecule drugs are most effective drugs and have minimal side-effects, which fuels the demand for the small molecule drugs. This fosters the growth of the small molecules segment as it attracts higher investments.

Regional Snapshot

North America dominated the global drug discovery outsourcing market in 2020. This is attributable to the presence of several top CROs, CMOs, and pharmaceutical companies in the region. Moreover, the favorable government regulations pertaining to the development and manufacturing of the new drugs is fueling the development of the drug discovery outsourcing market. Furthermore, the increased prevalence of chronic diseases among the US population has increased the investments in the drug discovery activities. It is estimated that around 60% of the US population is suffering from one or more chronic diseases. The geriatric population in US is estimated to reach around 90 million in US by 2050. Thus the drug discovery outsourcing market is expected to grow rapidly during the forecast period.

Asia Pacific is estimated to be the most opportunistic market during the forecast period. Asia Pacific is the home to few top contract research organization. Further, the favorable government policies is attracting FDIs and supplementing the expansion of drug developing companies in the region. Moreover, the rising awareness of the biologics, rising prevalence of chronic diseases, and growing geriatric population is estimated to have a significant impact on the market growth in Asia Pacific.

Table of Contents

Drug Discovery Outsourcing Market Scope

Report Coverage	Details
Market Size	US$ 6.55 Billion by 2030
Growth Rate	CAGR of 6.8% from 2022 to 2030
Largest Market	North America
Fastest Growing Market	Asia Pacific
Base Year	2021
Forecast Period	2022 to 2030
Segments Covered	Workflow, Therapeutic Area, Drug Type, Region

Drug Discovery Outsourcing Market Dynamics

Driver

Growing investments on the R&D by the pharmaceutical companies

The pharmaceutical companies are increasing their investments in the research and development for the development of new drugs. As per the International Federation of Pharmaceutical Manufacturers & Associations, the pharmaceutical industry spent around US$150 billion in the research & development activities. It is estimated that on an average, a pharmaceutical company spends around 17% of its revenues on the research & development. Therefore, the spurring investments in the R&D is expected to drive the market growth during the forecast period.

Restraint

High costs involved in the drug discovery activities

A high cost is involved in outsourcing the drug discovery activities. Moreover, the research and the clinical trials associated with the new drug development involves huge cost and involves huge amount of time to properly estimate the effects and side-effects of the newly developed drugs. Hence the high costs involved in drug discovery may restrict the small and medium pharmaceutical companies to indulge in the drug development process.

Opportunity

Rapid growth of the biologics industry

The recent developments of the various drugs in the biologics industry that can effectively treat the diseases like cancer, cardiovascular diseases, respiratory diseases, and diabetes is encouraging the biopharmaceutical companies to invest in the drug discovery activities.

Challenge

Candidate attrition rate is higher

The attrition rate of candidates is higher during the clinical trial phase of the drug development. This is a major challenge for the manufacturers as it involves huge cost and time for the retention and acquisition of new candidates.

Drug Discovery Outsourcing Market Companies

Albany Molecular Research Inc.
EVOTEC
Laboratory Corporation of America Holdings
GenScript
Pharmaceutical Product Development, LLC.
Charles River
WuXiAppTec
Merck & Co., Inc.
Thermo Fisher Scientific Inc.
Dalton Pharma Services
Oncodesign
Jubilant Biosys
DiscoverX Corporation
QIAGEN

Segments Covered in the Report

By Workflow

Target Identification & Screening
Lead Identification & Candidate Optimization
Target Validation & Functional Informatics
Preclinical Development
Others

By Therapeutic Area

Oncology
Cardiovascular
Gastrointestinal
Neurology
Respiratory
Others

By Drug Type

Biologics
Small Molecules

By Geography

North America
- U.S.
- Canada
Europe
- U.K.
- Germany
- France
Asia-Pacific
- China
- India
- Japan
- South Korea
- Malaysia
- Philippines
Latin America
- Brazil
- Rest of Latin America
Middle East & Africa (MEA)
- GCC
- North Africa
- South Africa
- Rest of the Middle East & Africa